Related Experiment Video
Updated: Nov 18, 2025

Hydra, a Computer-Based Platform for Aiding Clinicians in Cardiovascular Analysis and Diagnosis
Published on: September 26, 2018
[Fixed combination atorvastatin-perindopril (Lipercosyl®) for substitution treatment of cardiovascular risk
P Lancellotti1, A Ancion2, A J Scheen3
1ULiège, Service de Cardiologie, GIGA Cardiovasculaire, CHU Liège, Belgique.
Abstract:
Fixed combination atorvastatin-perindopril (Lipercosyl®) for substitution treatment of cardiovascular risk management Lipercosyl® is a fixed combination of atorvastatin and perindopril, a cholesterol-lowering and an antihypertensive agent, which allows blood pressure and cholesterol levels to be controlled in hypertensive patients with dyslipidemia : atorvastatin, an inhibitor of HMG-CoA reductase, and perindopril, an angiotensin converting enzyme inhibitor. Six presentations with different dosages of each molecule are available so the treatment can be individualized. Specific precautions of use to each medication must obviously be observed. The use of such a combination helps to ensure a good level of cholesterol while controlling blood pressure.
Related Concept Videos
Coronary Artery Disease V: Interprofessional Care
Atherosclerosis III: Management
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Peripheral Artery Disease III: Interprofessional Care
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...

